Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
(Date:7/3/2015)... Texas (PRWEB) , ... July ... ... biotechnology company providing industry-leading products for use in applications such as animal ... in wastewater treatment plants and restaurant kitchen settings, announced today that it ...
(Date:7/3/2015)... 3, 2015 Forskere ... Innovation in Science", som finner sted i ... på nett, på  http://www.openinnovationinscience.at , og søknadsperioden ... De to største utfordringene innen helsevitenskapen ... nye forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, ...
(Date:7/2/2015)... 2, 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today announced a litigation update. ... v. Verizon Services Corp. et al. , Case No. ... Eastern District of Virginia , the ... interpreting certain key claims in favor of the Defendants ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... is the first complement inhibitor to be tested ... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today that the Company,will be presenting its ... drug,candidate, POT-4, during the Retina Subspecialty Day at ...
... Oral Contraceptive,for the Prevention of Pregnancy, ... (NYSE: BRL ) today announced that ... approved its subsidiary Duramed Pharmaceuticals, Inc.,s New ... mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics, Proprietary microRNA Technologies and Strong IP ... Range of Plant-Based Applications, The Company has Recently Secured ... Trenches as Certain Milestones are ... Reached, Rosetta has Already Identified microRNAs Correlated With Algal Oil Content ...
Cached Biology Technology:Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... requires activation of a molecule on the surface of B ... uses in its insidious attack on the immune system, University ... Conference (AIDS 2006). , "The research supports a new role ... between cells, with important implications for future studies and drug ...
... Health today provided the clearest picture yet of the prevalence ... with an increased risk of breast cancer. The genes are ... In addition, the study identified key predictors for assessing which ... , Each year, approximately 200,000 women in the United States ...
... with a rare disease in which patients develop multiple, benign ... found throughout the body, according to a report in the ... results from the loss of a gene called CYLD, causing ... studies indicated a role for CYLD in inflammation, but the ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3Gene first linked to rare disease may trigger skin cancer, other tumors 2Gene first linked to rare disease may trigger skin cancer, other tumors 3
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... an expertise in the forefront of chemical ... synthesis and synthesis in solution. , Our ... and analytical HPLC at no extra cost, ... the highest quality standard. , Our team ...
... The new Thermo Electron RapidStak provides ... tasks. Utilizing a unique buffer nest technology ... loading, the RapidStak provides fast, reliable automation ... productivity and walk-away confidence. The RapidStak can ...
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
Biology Products: